Literature DB >> 1924172

Mutational analysis of the human p53 gene in malignant melanoma.

M Volkenandt1, U Schlegel, D M Nanus, A P Albino.   

Abstract

Nine metastatic melanoma cell lines and two melanocyte cell lines were analyzed for point mutations in highly conserved regions of the p53 gene. No mutations were detected in the two melanocytic cell lines and in eight melanoma cell lines. However, a C----T transition at codon 248, resulting in a substitution of tryptophan for arginine, was found in one melanoma cell line. On immunohistochemical staining, only this cell line showed reactivity for mouse monoclonal antibody 1801, which is immunoreactive with human p53 protein. The original paraffin-embedded specimen from which this mutant cell line was established was obtained, and sequence analysis detected the identical mutation in the p53 gene as that seen in the derived cell line. This is the first report indicating point mutations in the p53 gene in malignant melanocytic tissues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1924172     DOI: 10.1111/j.1600-0749.1991.tb00311.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  23 in total

1.  FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.

Authors:  Ethan V Abel; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  Point mutations and allelic loss in the TP53 locus of cutaneous malignant melanomas.

Authors:  J Weiss; W K Cavenee; R A Herbst; E G Jung; K C Arden
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

3.  Overexpression of p53 protein in basal cell carcinomas of human skin.

Authors:  C R Shea; N S McNutt; M Volkenandt; J Lugo; P G Prioleau; A P Albino
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

Review 4.  Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Authors:  Grant M Fischer; Y N Vashisht Gopal; Jennifer L McQuade; Weiyi Peng; Ralph J DeBerardinis; Michael A Davies
Journal:  Pigment Cell Melanoma Res       Date:  2017-11-02       Impact factor: 4.693

5.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

6.  Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.

Authors:  Jin Zhang; Xiangling Chen; Michael S Kent; Carlos O Rodriguez; Xinbin Chen
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

7.  Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin.

Authors:  M Yamamoto; H Takahashi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

9.  Expression of the p53 protein in malignant melanomas as a prognostic indicator.

Authors:  M Yamamoto; H Takahashi; K Saitoh; T Horikoshi; M Takahashi
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 10.  Growth factor independence and growth regulatory pathways in human melanoma development.

Authors:  U Rodeck
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.